DMAC Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Cash Position: As of March 31, 2026, DiaMedica reported cash, cash equivalents, and short-term investments of $51.3 million, down from $59.9 million at the end of 2025.
Current Liabilities: Increased to $5.7 million from $5.1 million.
Working Capital: Decreased to $46.6 million from $55.5 million.
Operating Cash Use: Net cash used in operating activities rose to $9.1 million from $7.1 million year-over-year.
R&D Expenses: Increased to $8 million from $5.7 million, primarily due to costs associated with the ReMEDy2 trial and additional reproductive toxicity testing.

2. Strategic Updates and Business Highlights

Clinical Progress: Enrollment in the ReMEDy2 stroke trial surpassed 70%, with the interim analysis expected by the end of 2026.
Preeclampsia Programs: Near completion of the Part 1a dose escalation study, with plans to initiate two additional cohorts (Part 1b and Part 2) for late and early onset preeclampsia, respectively, expected to start in the summer of 2026.
Global Expansion: The company is advancing its global Phase II study in early onset preeclampsia in Canada and the UK, with site selections completed and expected enrollment by year-end.

3. Forward Guidance and Outlook

Funding: Current cash reserves are anticipated to be sufficient to support clinical studies and operations through 2027.
R&D Expense Outlook: Expectation of moderate increases in R&D expenses as clinical trials progress, with no significant changes anticipated in general and administrative expenses.

4. Bad News, Challenges, or Points of Concern

Regulatory Delays: The FDA requested additional nonclinical studies due to adverse immune responses observed in a rabbit model, potentially delaying the IND submission process.
Increased Operating Losses: The rise in net cash used in operations reflects a growing net loss, which could raise concerns about financial sustainability if not managed effectively.
Clinical Risks: The interim analysis for the stroke program will include a futility analysis, which could lead to trial termination if no drug effect is observed.

5. Notable Q&A Insights

Preeclampsia Data: Investors are eager for updates on additional observations beyond blood pressure control, including potential improvements in edema and other biomarkers.
Enrollment Timelines: The initiation of the early onset preeclampsia study is contingent on finalizing dosing data and site preparations, with expectations set for later in 2026.
Interim Analysis Expectations: The interim analysis for the stroke program will determine if the trial continues or if a resample size adjustment is necessary, with a potential increase to between 300 and 700 patients based on initial results.

Overall, DiaMedica is making significant strides in its clinical programs, but faces challenges related to regulatory compliance and financial management as it seeks to validate the efficacy of DM199.

DMAC — DiaMedica Therapeutics Inc.